Outsourcing
Do you expect continued movement away from one-stop-shop outsourcing toward deeper modality-specific expertise?
Pharma's Almanac
PAO-06-26-RT-01Jun 29, 2026
Roundtable
How is the increasing complexity of modalities reshaping CDMO differentiation and specialization strategies?
Pharma's Almanac
PAO-05-26-RT-02May 27, 2026
Automation
How are companies distinguishing between “moonshot” automation and validated digital tools that can be deployed today?
Pharma's Almanac
PAO-05-26-RT-01May 1, 2026
Digital Tech
Which digital technologies have delivered tangible operational value over the past 12–18 months and which remain over-hyped?
Pharma's Almanac
PAO-04-26-RT-01Mar 30, 2026
Partnerships
What does a “true strategic partnership” between sponsors and CDMOs look like in today’s environment?
Pharma's Almanac
PAO-03-26-RT-01Mar 1, 2026
Drug Product
State of the Industry 2026 Virtual Panel: Drug Product
Nice Insight
PAO-26-SOTI-05Feb 9, 2026
Small Molecules
State of the Industry 2026 Virtual Panel: Small Molecules
Nice Insight
PAO-26-SOTI-04Feb 9, 2026
Breakthroughs
What emerging technologies or scientific breakthroughs do you believe will most reshape biopharma in the next 10 years?
Pharma's Almanac
PAO-02-26-RT-01Feb 2, 2026
Advanced Therapies
State of the Industry 2026 Virtual Panel: Advanced Therapies (pt. 2)
Nice Insight
PAO-26-SOTI-02Feb 2, 2026
Advanced Therapies
State of the Industry 2026 Virtual Panel: Advanced Therapies (pt. 1)
Nice Insight
PAO-26-SOTI-01Feb 2, 2026
Biologics
State of the Industry 2026 Virtual Panel: Biologics
Nice Insight
PAO-26-SOTI-03Jan 26, 2026
M&A
How are capital constraints impacting M&A and strategic partnerships in the CDMO and pharma sectors?
Pharma's Almanac
PAO-01-26-RT-02Jan 5, 2026
Innovations
Looking back over the last 30 years, what advance has had the greatest impact on the industry — and why?
Pharma's Almanac
PAO-01-26-RT-01Jan 5, 2026
GLP-1
How are GLP-1 therapies reshaping the pharmaceutical market — and what’s next?
Pharma's Almanac
PAO-11-25-RT-02Dec 1, 2025
API
What is driving renewed interest in small molecule therapeutics — and how is it shaping investment?
Pharma's Almanac
PAO-11-25-RT-01Dec 1, 2025
Threats
What do you see as the biggest threat to the CDMO industry in 2026 or beyond?
Pharma's Almanac
PAO-10-25-RT-03Nov 3, 2025
Technology
What do you consider to be the most important new tools or technology platforms currently being developed?
Pharma's Almanac
PAO-10-25-RT-02Nov 3, 2025
Market Trends
What economic or market trends are having the biggest impact on CDMO capacity and pipelines in 2025, and what will 2026 bring?
Pharma's Almanac
PAO-10-25-RT-01Nov 3, 2025
Rare Disease
What are the keys to making rare disease drug development sustainable?
Pharma's Almanac
PAO-09-25-RT-02Sep 25, 2025
PFDD
How are companies meaningfully incorporating patient voices into drug development decisions?
Pharma's Almanac
PAO-09-25-RT-01Sep 25, 2025